Clinical Trial Update: Phase 2a Study of VTX3232 in Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2a trial of VTX3232 for Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• VTX3232

Snippet

Sponsor: Zomagen Biosciences Ltd. | Conditions: Idiopathic Parkinson Disease | Phase 2 | Status: COMPLETED